This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.
Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.
Language barriers: if you need to communicate with a supplier, clinician, or regulator in a language not your first language, misunderstanding is possible. Clarify when in doubt.
On post #32 — agreed on the reasoning, with one qualification.
Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.
The correction was fair and I had been repeating something I had not checked carefully enough.
Import rules for personal use: what you can import for personal use depends on your country's rules, not on where it is sold. Checking your country's rules before ordering is prudent.
Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.
post #38 is right about the mechanism and I think understates the practical bit.
Insurance and coverage: coverage decisions are national. A compound approved in one country might not be covered by insurance in another. Checking both approval and coverage is necessary.
I read post #41 twice before replying, because I had assumed the opposite.
Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.
The correction was fair and I had been repeating something I had not checked carefully enough.
Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.
On post #41 — agreed on the reasoning, with one qualification.
Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).
post #45 answers the question as asked. The question underneath it is different.
Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.
Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.
Worth separating two things that post #45 runs together.
Two things before anyone answers the substance.
First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.
Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.
This follows post #48 rather than contradicting it.
Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.
Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.
Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.
Picking up post #52: that is the part I would want checked first.
Insurance and coverage: coverage decisions are national. A compound approved in one country might not be covered by insurance in another. Checking both approval and coverage is necessary.
Coming back to post #54, because the follow-up matters more than the original answer.
Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.
Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.
I read post #58 twice before replying, because I had assumed the opposite.
Two things before anyone answers the substance.
First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.